- Home
- MNTK vs AVTX Comparison
MNTK vs AVTX Comparison
Compare MNTK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNTK | AVTX |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.9M | 248.3M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNTK | AVTX |
|---|---|---|
| Price | $1.72 | $17.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $3.33 | ★ $30.14 |
| AVG Volume (30 Days) | 179.0K | ★ 376.5K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,682,000.00 | $192,000.00 |
| Revenue This Year | $2.45 | N/A |
| Revenue Next Year | $15.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $3.39 |
| 52 Week High | $4.96 | $19.41 |
Technical Indicators
Market Signals| Indicator | MNTK | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 53.79 |
| Support Level | $1.58 | $15.53 |
| Resistance Level | $1.80 | $18.80 |
| Average True Range (ATR) | 0.13 | 1.52 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 50.70 | 60.19 |
Price Performance
Historical ComparisonAbout MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).